Compounds > etoposide
Page last updated: 2024-08-23

etoposide and isoxazoles

etoposide has been researched along with isoxazoles in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's1 (16.67)18.2507
2000's3 (50.00)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cole, SP; Gerlach, JH; Mirski, SE1
Bonomi, P; Chang, A; Finkelstein, D1
Cherrington, JM; Kabbinavar, F; Mann, E; Schwartz, DP; Shawver, LK; Slamon, DJ; Strawn, LM1
Barrera, G; Edwards, PA; Gonzalez, FJ; Lee, FY; Lee, H; Vales, C; Willson, TM; Zhang, Y1
Beneytout, JL; Leger, DY; Liagre, B1
Aben, N; Avelar, AT; Berns, A; Cozijnsen, M; de Vries, H; Nagel, R; Proost, N; van de Ven, M; van der Vliet, J; Wessels, LFA1

Trials

1 trial(s) available for etoposide and isoxazoles

ArticleYear
Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study.
    American journal of clinical oncology, 1994, Volume: 17, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Isoxazoles; Lung Neoplasms; Male; Remission Induction; Survival Analysis

1994

Other Studies

5 other study(ies) available for etoposide and isoxazoles

ArticleYear
Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
    Cancer research, 1987, May-15, Volume: 47, Issue:10

    Topics: Animals; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cell Line; Colchicine; Daunorubicin; Doxorubicin; Drug Resistance; Enzyme-Linked Immunosorbent Assay; Epirubicin; Etoposide; Glycoproteins; Gramicidin; Humans; Immunosorbent Techniques; Isoxazoles; Lung Neoplasms; Menogaril; Mice; Mice, Inbred BALB C; Mitoxantrone; Nogalamycin; Phenotype; Vinblastine; Vincristine

1987
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Division; Cell Survival; Cisplatin; Etoposide; Glioblastoma; Head and Neck Neoplasms; Humans; Isoxazoles; Leflunomide; Lung Neoplasms; Mice; Mice, Nude; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2000
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.
    Proceedings of the National Academy of Sciences of the United States of America, 2006, Jan-24, Volume: 103, Issue:4

    Topics: 3-Hydroxybutyric Acid; Adenoviridae; Animals; Blood Glucose; Blotting, Northern; Blotting, Western; Cholesterol; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Etoposide; Gluconeogenesis; Glucose; Glycogen; Hepatocytes; Hyperglycemia; Hyperlipidemias; Insulin; Insulin Resistance; Isoxazoles; Lipids; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Models, Statistical; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Time Factors; Transcription Factors; Triglycerides

2006
Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents.
    Apoptosis : an international journal on programmed cell death, 2006, Volume: 11, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Proliferation; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Activation; Etoposide; Humans; Isoxazoles; K562 Cells; Leflunomide; Leukemia, Erythroblastic, Acute; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; NF-kappa B; Organophosphorus Compounds; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Staurosporine

2006
Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
    Molecular cancer therapeutics, 2019, Volume: 18, Issue:4

    Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Survival; Checkpoint Kinase 1; Cisplatin; CRISPR-Associated Protein 9; DNA Damage; Drug Synergism; Etoposide; Humans; Isoxazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Small Cell Lung Carcinoma; Tumor Burden; Xenograft Model Antitumor Assays

2019